A cost-benefit/cost-effectiveness analysis of proposed supervised injection facilities in Montreal
The paper determines whether expanding Insite (North American’s first and only supervised injection facility) to more locations in Canada such as Montreal, cost less than the health care consequences of not having such expanded programs for injection drug users.
Open